# Technology Brief: Plasma Protein Biomarkers for Diagnosis of Ovarian Cancer

**Docket Number:** 06B098

## Summary
- There is a great need for a reliable way to diagnose ovarian cancer, especially in the early stages.
- Analysis of markers in blood offers many advantages in terms of cost and ease of sampling.
- Researchers at Moffitt Cancer Center have identified a panel of 21 proteins from patient plasma that correlate with ovarian cancer.

## Features and Benefits
- The 21 proteins are differentially expressed in plasma, affording easy sampling from the patient.
- The panel is based on a large sample size of 160 women, improving reliability of the results.
- Eight of the proteins are differentially expressed in early stage ovarian cancer, where there is a great need for a reliable test.
- The protein panel offers promise as a clinical test for diagnosis, screening and monitoring therapy in ovarian cancer.

## Stage of Development
An assay is being developed for clinical validation studies.

## Inventors
Drs. R. Sutphen and J. Lancaster

## Patents
Patent application pending.

## Contact Information:

**Haskell Adler PhD MBA**  
Senior Licensing Manager  
Email: haskell.adler@moffitt.org  
Telephone: 813-745-6596

**H. Lee Moffitt Cancer Center and Research Institute, Inc.**  
Office of Technology Management and Commercialization  
12902 Magnolia Drive MRC-TTO  
Tampa, FL 33612  
Website: http://www.moffitt.org/OTMC